ArticleCancer biology & medicine2020
Serum miR-339-3p as a potential diagnostic marker for non-small cell lung cancer.
Article in Cancer biology & medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Biomarkers Suitable for Early Detection of Intrathoracic Cancers in Primary Care: A Systematic Review.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2025Pooled it
- FeBioengineering (Basel, Switzerland) · 2026Article
- Exploring shared microRNA profiles in liquid-based cytology and plasma as biomarkers of high-grade intraepithelial lesions.Scientific reports · 2025Article
- LncRNA FAM66C predicts poor prognosis in patients with lung adenocarcinoma and regulates cell proliferation and metastasis via miR-339-3p.Journal of cardiothoracic surgery · 2025Article
- Circulating cell-free and extracellular vesicles-derived microRNA as prognostic biomarkers in patients with early-stage NSCLC: results from RESTING study.Journal of experimental & clinical cancer research : CR · 2024Observational
- hsa_circ_0020378 regulating miR-339-3p/COL1A1 promotes osteosarcoma progression.Cancer biology & therapy · 2023Article
- Exploring the Potential of Non-Coding RNAs as Liquid Biopsy Biomarkers for Lung Cancer Screening: A Literature Review.Cancers · 2023Review
- Circulating noncoding RNAs: promising biomarkers in liquid biopsy for the diagnosis, prognosis, and therapy of NSCLC.Discover oncology · 2023Review
- Non-coding RNAs in lung cancer: molecular mechanisms and clinical applications.Frontiers in oncology · 2023Review
- miR-339-3p inhibits cell growth and epithelial-mesenchymal transition in nasopharyngeal carcinoma by modulating the KAT6A/TRIM24 axis.International journal of clinical oncology · 2022Article
- MiR-378a-3p acts as a tumor suppressor in gastric cancerCancer biology & medicine · 2022Article
- Long Noncoding RNA FBXL19-AS1-Mediated Ulcerative Colitis-Associated Intestinal Epithelial Barrier Defect.Tissue engineering and regenerative medicine · 2022Article
- Diagnostic and prognostic value of serum miR-145 and vascular endothelial growth factor in non-small cell lung cancer.Oncology letters · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.